This article is more than 5 years old. Information may no longer be current.

NuVasive obtains add-on payment for magnetically controlled EOS growth rods

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NuVasive Inc. announced the CMS has given the company a new technology add-on payment for the MAGEC system of magnetically controlled growth rods.

The MAGEC system is the only FDA-cleared, magnetically controlled growth modulation system for pediatric spinal deformity. The system helps surgeons with reducing surgeries needed for early onset scoliosis treatment, according to a NuVasive press release.

“CMS’s decision will significantly improve patient access to MAGEC, which is quickly becoming the standard of care for pediatric patients with [early onset scoliosis] EOS,” Gregory T. Lucier, chairman and chief executive officer of NuVasive, said in the release. “The innovative MAGEC rod can be extended noninvasively with a magnet, reducing the number of planned distraction surgeries from up to 15, to only a single one. By transforming the experience for these patients, NuVasive is able to help minimize the risks associated with multiple surgeries, while also reducing the total cost of care.”

Lucier noted in the release NuVasive plans to continue to work with providers and payers to improve access to this technology.

Reportedly, as of October 1, 2016, the new technology add-on payment will allow U.S. hospitals and health systems that use MAGEC to treat patients with EOS to receive reimbursement from CMS.

Reference: